ARSU.F Stock Overview
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Fagron NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €18.59 |
| 52 Week High | €19.26 |
| 52 Week Low | €16.15 |
| Beta | 0.28 |
| 1 Month Change | 0% |
| 3 Month Change | 1.92% |
| 1 Year Change | -0.86% |
| 3 Year Change | -17.55% |
| 5 Year Change | 2.59% |
| Change since IPO | -65.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| ARSU.F | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 1.2% |
| 1Y | -0.9% | 3.6% | 24.7% |
Return vs Industry: ARSU.F underperformed the US Healthcare industry which returned 4% over the past year.
Return vs Market: ARSU.F underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| ARSU.F volatility | |
|---|---|
| ARSU.F Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.2% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ARSU.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ARSU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,282 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.
Fagron NV Fundamentals Summary
| ARSU.F fundamental statistics | |
|---|---|
| Market cap | US$1.37b |
| Earnings (TTM) | US$75.14m |
| Revenue (TTM) | US$812.64m |
18.2x
P/E Ratio1.7x
P/S RatioIs ARSU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARSU.F income statement (TTM) | |
|---|---|
| Revenue | €762.99m |
| Cost of Revenue | €430.38m |
| Gross Profit | €332.61m |
| Other Expenses | €262.07m |
| Earnings | €70.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | 0.97 |
| Gross Margin | 43.59% |
| Net Profit Margin | 9.25% |
| Debt/Equity Ratio | 69.7% |
How did ARSU.F perform over the long term?
See historical performance and comparison